Abstract
Around 40% of patients with breast cancer will present with a recurrence of the disease. Chemotherapy is recommended for patients with recurrent hormone-independent or hormone-refractory breast cancer and almost all patients with metastatic breast cancer (MBC) receive chemotherapy during their medical history. Nanoparticle albuminbound (nab)-paclitaxel is a solvent-free, 130-nanometer particle formulation of paclitaxel. Nab-paclitaxel can be administered to all patients for whom the treatment choice is a taxane. In this review, 6 patient profiles for which nabpaclitaxel may be particularly useful are described and analyzed: (i) as first-line treatment of MBC, (ii) as second-line treatment of MBC after oral chemotherapy, (iii) after a standard taxane, (iv) as third-line treatment after a standard taxane and oral chemotherapy, (v) for patients with HER2-positive MBC and (vi) for patients with intolerance to standard taxanes. Nab-paclitaxel is a rational treatment choice for patients with MBC in different settings, as well as for those with prior exposure to a standard taxane.
Keywords: Capecitabine, chemotherapy, docetaxel, MBC, nab-paclitaxel, paclitaxel.
Current Cancer Drug Targets
Title:Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile
Volume: 16 Issue: 5
Author(s): José Ángel García-Sáenz, Miguel Martín, Pilar Zamora, Ignasi Tusquets, Miguel Ángel Seguí, Ana Santaballa, Pedro Sánchez-Rovira, Manuel Ruiz, Álvaro Rodríguez-Lescure, Arrate Plazaola, Eduardo Martínez de Dueñas, Noelia Martínez-Jáñez, Guillermo López-Vivanco, Rafael López, Juan de la Haba, Antonio González-Martín, Andrés García-Palomo, Elena Galve, Lourdes Calvo, Norberto Batista, Agustí Barnadas, Francisco Ayala de la Peña, José Manuel Aramendía, Isabel Álvarez, Raquel Andrés, Ana Lluch, Antonio Llombart, Javier Cortés, Eva Ciruelos and Emilio Alba
Affiliation:
Keywords: Capecitabine, chemotherapy, docetaxel, MBC, nab-paclitaxel, paclitaxel.
Abstract: Around 40% of patients with breast cancer will present with a recurrence of the disease. Chemotherapy is recommended for patients with recurrent hormone-independent or hormone-refractory breast cancer and almost all patients with metastatic breast cancer (MBC) receive chemotherapy during their medical history. Nanoparticle albuminbound (nab)-paclitaxel is a solvent-free, 130-nanometer particle formulation of paclitaxel. Nab-paclitaxel can be administered to all patients for whom the treatment choice is a taxane. In this review, 6 patient profiles for which nabpaclitaxel may be particularly useful are described and analyzed: (i) as first-line treatment of MBC, (ii) as second-line treatment of MBC after oral chemotherapy, (iii) after a standard taxane, (iv) as third-line treatment after a standard taxane and oral chemotherapy, (v) for patients with HER2-positive MBC and (vi) for patients with intolerance to standard taxanes. Nab-paclitaxel is a rational treatment choice for patients with MBC in different settings, as well as for those with prior exposure to a standard taxane.
Export Options
About this article
Cite this article as:
Ángel García-Sáenz José, Martín Miguel, Zamora Pilar, Tusquets Ignasi, Ángel Seguí Miguel, Santaballa Ana, Sánchez-Rovira Pedro, Ruiz Manuel, Rodríguez-Lescure Álvaro, Plazaola Arrate, Martínez de Dueñas Eduardo, Martínez-Jáñez Noelia, López-Vivanco Guillermo, López Rafael, de la Haba Juan, González-Martín Antonio, García-Palomo Andrés, Galve Elena, Calvo Lourdes, Batista Norberto, Barnadas Agustí, Ayala de la Peña Francisco, Manuel Aramendía José, Álvarez Isabel, Andrés Raquel, Lluch Ana, Llombart Antonio, Cortés Javier, Ciruelos Eva and Alba Emilio, Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile, Current Cancer Drug Targets 2016; 16 (5) . https://dx.doi.org/10.2174/1568009615666150817121731
DOI https://dx.doi.org/10.2174/1568009615666150817121731 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clomiphene Citrate, Metformin or Both for Ovulation Induction in Therapy Naïve Women with Polycystic Ovary Syndrome (PCOS)? A Descriptive Review
Current Drug Therapy LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers
Current Cancer Drug Targets Immunity to Tuberculosis and Novel Therapeutic Strategies
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Nucleic Acid Aptamers: Clinical Applications and Promising New Horizons
Current Medicinal Chemistry An Update on Extemporaneous Preparation of Radiopharmaceuticals Using Freeze-Dried Cold Kits
Mini-Reviews in Medicinal Chemistry Actions of the Anti-Angiogenic Compound Angiostatin in an Animal Model of Alzheimer’s Disease
Current Alzheimer Research Pyrano[3,2-c]quinoline Derivatives as New Class of α-glucosidase Inhibitors to Treat Type 2 Diabetes: Synthesis, in vitro Biological Evaluation and Kinetic Study
Medicinal Chemistry Design, Synthesis and Biochemical Evaluation of Estrogen Receptor Ligand Conjugates as Tumour Targeting Agents
Letters in Drug Design & Discovery Ginsenoside Rh2 Inhibits Migration of Lung Cancer Cells under Hypoxia via mir-491
Anti-Cancer Agents in Medicinal Chemistry Developmental Expression of the Translocator Protein 18 kDa (TSPO) in Testicular Germ Cells
Current Molecular Medicine Synthesis of Novel Pyridine Bearing Biologically Active Imidiazolyl, Pyrazolyl, Oxa/thiadiazolyl and Urea Derivatives as Promising Anticancer Agents
Current Organic Synthesis On the Role of Rab5 in Cell Migration
Current Molecular Medicine The Role of Tumor Suppressor DLC-1: Far From Clear
Anti-Cancer Agents in Medicinal Chemistry Hybrid Molecules Incorporating Natural Products: Applications in Cancer Therapy, Neurodegenerative Disorders and Beyond
Current Medicinal Chemistry Beta-Blockers: Current State of Knowledge and Perspectives
Mini-Reviews in Medicinal Chemistry Antineoplastic Potential of Medicinal Plants
Recent Patents on Biotechnology Cucurbitacin B Induces DNA Damage, G2/M Phase Arrest, and Apoptosis Mediated by Reactive Oxygen Species (ROS) in Leukemia K562 Cells
Anti-Cancer Agents in Medicinal Chemistry Heavy Metals and Epigenetic Alterations in Brain Tumors
Current Genomics Neural and Behavioral Responses to Systemic Immunologic Stimuli: A Consideration of Bacterial T Cell Superantigens
Current Pharmaceutical Design Chalcones in Cancer: Understanding their Role in Terms of QSAR
Current Medicinal Chemistry